A comparison of the mixed and sequential use of acetaminophen and dexketoprofen in painful vaso-occlusive crises.
Eur J Clin Pharmacol
; 80(3): 475-480, 2024 Mar.
Article
en En
| MEDLINE
| ID: mdl-38245872
ABSTRACT
PURPOSE:
Opioids are widely used to treat painful vaso-occlusive crises (VOC) in sickle cell disease (SCD). However, due to opioids' significant adverse effect profiles, the search for alternative therapies continues from the past to the present. The study aimed to investigate the efficacy of acetaminophen and dexketoprofen in the treatment of painful VOC.METHODS:
This study is a single-center, prospective, non-randomized, single-blinded, controlled study. The study comprised two groups the first administered acetaminophen and dexketoprofen mixed group, while the second received them sequential group. Opioids were used in patients with persistent pain despite these analgesics. Demographic and laboratory information, pain scores, opioid requirement, dose amount, side effects, and length of hospital stay of the patients were recorded.RESULTS:
The study comprised 56 (100%) patients with painful VOC, 29 (51.8%) from the mixed group, and 27 (48.2%) from the sequential group. Opioid use was seen in 16 (55.2%) patients in the mixed group and 21 (77.8%) patients in the sequential group (p = 0.074). The median amount of opioid used was significantly lower in the mixed group than in the sequential group (p < 0.001). Also, the median length of hospital stay was significantly lower in the mixed group than in the sequential group (p < 0.001).CONCLUSION:
Our study suggests that administering acetaminophen and dexketoprofen in the mix for the treatment of painful VOC in patients with SCD may be a more efficient approach compared to sequential administration. This approach appears to reduce opioid usage and shorten hospital stays.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Trometamina
/
Cetoprofeno
/
Compuestos Orgánicos Volátiles
/
Anemia de Células Falciformes
Tipo de estudio:
Clinical_trials
Idioma:
En
Revista:
Eur J Clin Pharmacol
Año:
2024
Tipo del documento:
Article